Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
After-Hours Stock Movers 01/05: (CNAT) (ICON) (BLUE) Higher; (EPZM) (CEMP) (OTIC) Lower (more...)
January 5, 2016 6:12 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) 15% HIGHER; three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences between treatment and placebo groups in baseline Model for End-stage Liver Disease (MELD)1 score and disease etiology as specified in the trial statistical analysis plan.
Epizyme, Inc. (NASDAQ: EPZM) 10% LOWER; announced that it intends to... More
Conatus Pharmaceuticals (CNAT) Resumes Trading; Shares Up 10%
January 5, 2016 4:38 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month, double-blind, placebo-controlled stage... More
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ET
January 5, 2016 4:11 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 4.35 PM ET
... MoreConatus Pharmaceuticals (CNAT) Emricasan Phase 2 Liver Cirrhosis Trial Shows Statistically Significant Reduction in cCK18
January 5, 2016 4:07 PM ESTConatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced that the three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences... More
Conatus Pharmaceuticals (CNAT) halted, news pending
January 5, 2016 4:01 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) halted, news pending
... More